Clinical Research Directory
Browse clinical research sites, groups, and studies.
Evaluation of Cemiplimab in Combination With Platinum-Doublet Chemotherapy in First-Line (1L) Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) in Adult United States (US) Patients
Sponsor: Regeneron Pharmaceuticals
Summary
This multi-year cohort study will assess the real-world safety and effectiveness of 1L treatment with cemiplimab in combination with platinum-doublet chemotherapy across advanced NSCLC patient subgroups defined by age, sex, race, and ethnicity. Patients will be retrospectively identified from at least two US electronic health record (EHR)-based databases.
Official title: Evaluating the Safety and Effectiveness of Cemiplimab in Combination With Platinum-Doublet Chemotherapy by Demographic Characteristics in First-Line Treatment of Advanced Non-Small Cell Lung Cancer: A Multi-Database Real World Evidence Study in US Patients
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
OBSERVATIONAL
Enrollment
1000
Start Date
2024-02-21
Completion Date
2027-06-23
Last Updated
2025-08-27
Healthy Volunteers
No
Conditions
Interventions
REGN2810
No study specific interventions for this non-interventional-observational study; patients had previously been administered this treatment.
Platinum-doublet chemotherapy
No study specific interventions for this non-interventional-observational study; patients had previously been administered this treatment.
Locations (1)
Regeneron Research Facility
Tarrytown, New York, United States